Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

J Biomol Struct Dyn. 2021 Apr;39(7):2673-2678. doi: 10.1080/07391102.2020.1752802. Epub 2020 Apr 16.

Authors

Nisha Muralidharan¹, R Sakthivel¹, D Velmurugan², M Michael Gromiha¹

Affiliations

¹ Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, India.
² School of Bioengineering, Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Chennai, India.

PMID: 32248766
DOI: 10.1080/07391102.2020.1752802

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Drug Combinations
Drug Repositioning
Humans
Lopinavir
Oseltamivir
Peptide Hydrolases
Ritonavir*
SARS-CoV-2

Substances

Antiviral Agents
Drug Combinations
Oseltamivir
Lopinavir
Peptide Hydrolases
Ritonavir